Adjuvant trastuzumab for breast cancer: Assessing HER2/neu status incurs more costs for treatment

Por Kell, Malcolm R, Power, Colm P
Publicado em 2005

Management of Unusual Histological Types of Breast Cancer

Por Cadoo, Karen A., McArdle, Orla, O'Shea, Anne-Marie, Power, Colm P., Hennessy, Bryan T.
Publicado em 2012

The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy

Por Hannan, Enda J., O’Leary, Donal P., MacNally, Stephen P., Kay, Elaine W., Farrell, Michael A., Morris, Patrick G., Power, Colm P., Hill, Arnold D.K.
Publicado no Medicine (Baltimore) (2017)